Elite Pharmaceuticals Inc (ELTP)

Name: Elite Pharmaceuticals Inc (ELTP) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name ELITE PHARMACEUTICALS INC /NV/ · CIK 0001053369 · OTC · Pharmaceutical Preparations

Sector Manufacturing
Incorporated NJ
Fiscal year ends Mar 31

For the year ended 2026-03-31, Elite Pharmaceuticals Inc reported revenue of $148.87M. Revenue grew 77.1% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $141.01M.

Key ratios (year ended 2026-03-31)

50.4%

Gross margin

33.0%

Operating margin

30.1%

Net margin

45.4%

Return on year-end equity

77.1%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-19

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-03-31	2017-03-31
Revenue	$141.01M	$148.87M	$84.04M	$56.63M	$34.16M	$32.26M	$25.38M	$17.99M	$7.57M	$7.46M	$9.64M
Cost of Revenue	$79.71M	$73.85M	$43.96M	$30.27M	$17.56M	$17.47M	$13.51M	$10.02M	$4.70M	$3.51M	$5.90M
Gross Profit	$61.31M	$75.02M	$40.09M	$26.36M	$16.59M	$14.80M	$11.87M	$7.98M	$2.87M	$3.95M	$3.74M
R&D Expense	$6.10M	$5.74M	$7.96M	$6.88M	$6.20M	$4.05M	$5.11M	$5.53M	$7.60M	$9.62M	$8.30M
Operating Income	$34.94M	$49.11M	$19.60M	$10.79M	$3.68M	$5.07M	$2.10M	-$2.29M	-$9.16M	-$9.05M	-$7.36M
Depreciation & Amortization	$1.05M	$1.07M	$1.23M	$1.32M	$1.28M	$1.21M	$1.31M	$1.32M	$1.26M	$996.4K	$714.5K
EBITDA	$35.99M	$50.18M	$20.83M	$12.11M	$4.95M	$6.28M	$3.42M	-$965.6K	-$7.90M	-$8.05M	-$6.64M
Net Income	$56.67M	$44.87M	-$4.31M	$20.11M	$3.56M	$8.90M	$5.09M	-$2.24M	-$9.28M	-$3.67M	$3.81M
EPS (Diluted)	n/a	$0.03	$0.00	$0.02	$0.00	$0.01	$0.00	$0.00	-$0.01	-$0.01	-$0.01
Total Assets	$139.67M	$138.29M	$96.39M	$83.65M	$40.90M	$35.15M	$26.19M	$24.96M	$24.40M	$30.88M	$34.31M
Total Liabilities	$34.84M	$39.41M	$42.87M	$26.07M	$11.94M	$9.93M	$10.04M	$14.30M	$13.01M	$12.41M	$8.65M
Long-Term Debt	n/a	n/a	n/a	n/a	n/a	$1.36M	$1.47M	$1.57M	n/a	n/a	n/a
Shareholders' Equity	$104.83M	$98.88M	$53.52M	$57.58M	$28.96M	$25.22M	$16.15M	$10.66M	-$2.51M	$4.57M	$25.66M
Cash & Equivalents	n/a	n/a	n/a	$7.11M	$7.83M	$8.54M	$3.19M	$1.13M	$2.28M	$7.18M	$10.59M
Operating Cash Flow	$19.04M	$23.75M	$7.46M	-$3.24M	$3.34M	$6.51M	$3.19M	-$1.79M	-$6.79M	-$4.81M	-$7.88M
Capital Expenditures	$1.52M	$925.6K	$1.63M	$809.7K	$5.74M	$498.6K	n/a	n/a	n/a	n/a	n/a
Free Cash Flow	$17.53M	$22.82M	$5.83M	-$4.04M	-$2.40M	$6.01M	n/a	n/a	n/a	n/a	n/a
Shares Outstanding	1.08B	1.08B	1.07B	1.07B	1.01B	1.01B	1.01B	840.40M	824.85M	802.53M	927.93M
Weighted Average Diluted Shares	n/a	1.14B	1.07B	1.02B	1.01B	1.01B	943.00M	993.26M	816.31M	798.17M	844.51M
EPS (Basic)	n/a	$0.04	$0.00	$0.02	$0.00	$0.01	$0.01	$0.00	-$0.01	$0.00	$0.03